Siegrist Jonathan Philip 4

What Happened
Jonathan Philip Siegrist, EVP of R&D & Chief Technology Officer at QuidelOrtho Corporation (QDEL), was granted a total of 72,302 restricted stock units (RSUs) on January 30, 2026. The Form 4 reports two derivative awards: 36,152 RSUs and 36,150 RSUs, each recorded at $0.00 on the grant date (these are non‑cash equity awards that convert to shares on vesting).

Key Details

• Transaction date: January 30, 2026; Filing date (Form 4): February 3, 2026 (filed within the normal 2-business‑day window).
• Grants: 36,152 RSUs (first grant) and 36,150 RSUs (second grant); total = 72,302 RSUs. Price reported: $0.00 (award).
• Vesting (from footnotes):
  • The 36,152‑share grant: 12,050 RSUs vest on Jan 30, 2027; remaining 24,102 vest in equal installments on Jan 30, 2028 and Jan 30, 2029.
  • The 36,150‑share grant: vests in equal installments on Jan 30 of 2027, 2028 and 2029.
• Each RSU represents the right to receive one share of common stock upon vesting.
• Shares owned after the transaction are not specified in the provided filing excerpt.
• No 10b5‑1 plan, immediate sale, tax‑withholding, or late‑filing flags indicated in the provided details.

Context
These entries are equity awards (derivative RSUs), not open‑market purchases or sales. RSU grants are standard compensation for executives and do not involve cash changing hands at grant; they become shares only as the RSUs vest per the schedules above. Such awards are common and should be interpreted as part of executive compensation rather than a direct buy/sell signal.